Kyntra Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| FG-3246 Phase 2 Monotherapy Interim Analysis | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
FG-3246 Phase 2 Monotherapy Trial Enrollment QuarterlyTarget: 75 participants
Cash Runway Extension Annually2K
Watch Items
- FG-3246 Phase 2 Monotherapy Interim AnalysisTrigger: Interim data readout in Q4 2026Action: Evaluate progression-free survival (PFS) and safety profile to validate monotherapy efficacy.
- Pivotal Phase 3 Roxadustat Trial Initiation in LR-MDSTrigger: Trial initiation in 2H 2026Action: Confirm finalization of protocol with FDA and start patient enrollment.
Research as of 24 Jul 2026